cobiprostone
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00597818)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Chloride channel protein 2ACTIVATOR
CLCN2 activator
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](C)CC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O1- Mol. weight
- 404.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103799 ↗
Also known as
- cobiprostone
- cobiprostone
- cobiprostone
- cobiprostone
- ru-8811
- ru-8811
- spi-8811
- spi-8811
- spi-8811
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02542215 | Phase 2 | Jun 1, 2015 | Sucampo, University of Connecticut |
| NCT00737594 | Phase 2 | Jul 1, 2008 | Sucampo, The University of Texas, Dallas |
| NCT00597818 | Phase 2 | Aug 1, 2007 | Department of Veteran Affairs, Sucampo |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sucampo | For profit | 3 | 3 | 1 | 2007 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 2007 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Connecticut | Academic/Hospital | 1 | 0 | 1 | 2015 |
4 organizations
Page 1 / 1